FDA expands TearCare’s indication, making it the first and only treatment for MGD indicated to improve meibomian gland function in adults with evaporative dry eye disease. https://ow.ly/wxbY50ZHlzz
Eyewire+
Book and Periodical Publishing
Wayne, PA 13,519 followers
Eyewire+ is devoted to keeping readers updated with the latest information in the ophthalmic and eye care fields.
About us
Eyewire+ keeps readers updated with the latest in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, videos, and other news sources. EyewireTV is the only weekly news broadcast devoted entirely to the ophthalmic industry.
- Website
-
https://eyewire.news/
External link for Eyewire+
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- Wayne, PA
- Specialties
- eye care, optometry, opthalmology, ophthalmics, doctors, medicine, med students, media, publishing, and news
Updates
-
Moorfields researchers reported that a first-in-human stem cell treatment improved vision in nine patients with aniridia-related keratopathy in a JAMA Ophthalmology study: https://lnkd.in/eMu2Wma5
-
CMS issued updated guidance on prior authorization transparency, saying plans must make policies and performance data accessible and understandable to patients and physicians: https://lnkd.in/epMjC_xH
-
Duravyu did not meet the primary endpoint in EyePoint’s phase 3 LUGANO trial in wet AMD, but it reduced treatment burden by 42% versus on-label aflibercept 2 mg: https://lnkd.in/eM27KGRp
-
WCO, Alcon and IACLE are expanding access to dry eye education tools for instructors, educators and students through IACLETOP: https://lnkd.in/euVB5qcj
-
CORE has published Issue 91 of Contact Lens Update on presbyopia communication, with an editorial, feature article, patient handout and conference highlight: https://lnkd.in/e5E5jDRi
-
UK study of 2,858 eyes found anti-VEGF's protective effect against PDR was strongest soon after treatment and faded by about 4 weeks: https://lnkd.in/e6yNTme2
-
European consortium begins recruiting for 2 trials of gene-silencing eye drops for rare corneal diseases, with studies underway in Cologne: https://lnkd.in/ehdQ_gsk
-
Annexon added a Month 24 dual primary endpoint to its phase 3 ARCHER II trial of vonaprument for geographic atrophy, while retaining the Month 15 endpoint: https://lnkd.in/gVCan9pU
-
Prevent Blindness says proposed Head Start changes could weaken vision screening standards and create inconsistencies in early detection and follow-up care: https://lnkd.in/eihNDDk3